• LAST PRICE
    6.0100
  • TODAY'S CHANGE (%)
    Trending Down-0.1200 (-1.9576%)
  • Bid / Lots
    6.0100/ 23
  • Ask / Lots
    6.0200/ 16
  • Open / Previous Close
    6.2000 / 6.1300
  • Day Range
    Low 6.0100
    High 6.2888
  • 52 Week Range
    Low 4.0300
    High 8.9600
  • Volume
    1,264,867
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 6.13
TimeVolumeBCRX
09:32 ET442436.24
09:34 ET72216.265
09:36 ET56406.25
09:38 ET125516.25
09:39 ET78346.2188
09:41 ET68656.215
09:43 ET30136.2001
09:45 ET88536.21
09:48 ET33846.225
09:50 ET163406.245
09:52 ET21846.25
09:54 ET130916.2888
09:56 ET227086.2266
09:57 ET58716.21
09:59 ET25006.215
10:01 ET379206.175
10:03 ET139186.195
10:06 ET80216.16
10:08 ET52826.155
10:10 ET46726.15
10:12 ET209136.19
10:14 ET82266.21
10:15 ET25096.23
10:17 ET98196.245
10:19 ET4006.25
10:21 ET66476.245
10:24 ET234446.26
10:26 ET82786.26
10:28 ET98726.245
10:30 ET11006.25
10:32 ET61196.255
10:33 ET46586.25
10:35 ET42006.275
10:37 ET54086.26
10:39 ET62806.255
10:42 ET46076.255
10:44 ET81646.255
10:46 ET20406.255
10:48 ET147846.25
10:50 ET183126.255
10:51 ET24006.2501
10:53 ET238516.215
10:55 ET22846.21
10:57 ET11736.21
11:00 ET82846.205
11:02 ET194986.215
11:04 ET52346.23
11:06 ET16086.235
11:08 ET33396.22
11:09 ET35656.215
11:11 ET91056.195
11:13 ET204866.195
11:15 ET118706.175
11:18 ET63836.175
11:20 ET113676.19
11:22 ET95756.19
11:24 ET187626.175
11:26 ET435096.165
11:27 ET61946.16
11:29 ET107046.155
11:31 ET159476.175
11:33 ET66796.16
11:36 ET98356.165
11:38 ET29376.17
11:40 ET251566.165
11:42 ET10006.1675
11:44 ET21006.1675
11:45 ET7956.165
11:47 ET209056.145
11:49 ET37106.1406
11:51 ET13006.145
11:54 ET62376.145
11:56 ET20966.14
11:58 ET31696.145
12:00 ET26116.145
12:02 ET68016.135
12:03 ET73646.125
12:05 ET57006.11
12:07 ET74766.1
12:09 ET5636.105
12:12 ET139706.1
12:14 ET69616.11
12:16 ET15006.11
12:18 ET145756.1
12:20 ET391566.08
12:21 ET127276.1
12:23 ET107346.09
12:25 ET51576.095
12:27 ET46066.095
12:30 ET47726.085
12:32 ET173906.085
12:34 ET17246.08
12:36 ET10726.085
12:38 ET239046.1
12:39 ET81086.105
12:41 ET71296.105
12:43 ET9006.105
12:45 ET10506.105
12:48 ET270616.085
12:50 ET58006.075
12:52 ET5006.07
12:54 ET20646.075
12:56 ET138076.055
12:57 ET113546.055
12:59 ET352256.05
01:01 ET110596.045
01:03 ET87376.03
01:06 ET226416.02
01:08 ET110276.0157
01:10 ET44446.01
01:12 ET48086.015
01:14 ET116966.02
01:15 ET137496.025
01:17 ET7856.025
01:19 ET103686.02
01:21 ET16416.015
01:24 ET32256.01
01:26 ET4006.01
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBCRX
BioCryst Pharmaceuticals Inc
1.3B
-5.6x
---
United StatesMDXG
MiMedx Group Inc
1.1B
20.1x
---
United StatesKNSA
Kiniksa Pharmaceuticals Ltd
1.4B
221.7x
---
United StatesVCYT
Veracyte Inc
1.6B
-23.0x
---
United StatesDNA
Ginkgo Bioworks Holdings Inc
1.5B
-1.4x
---
United StatesGLPG
Galapagos NV
1.8B
53.5x
---
As of 2024-05-28

Company Information

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Contact Information

Headquarters
4505 Emperor Blvd Ste 200DURHAM, NC, United States 27703-8457
Phone
919-859-1302
Fax
919-859-1314

Executives

Independent Chairman of the Board
Nancy Hutson
President, Chief Executive Officer, Director
Jon Stonehouse
Chief Financial Officer
Anthony Doyle
Chief Commercial Officer
Charles Gayer
Chief Research & Development Officer
Helen Thackray

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.3B
Revenue (TTM)
$355.4M
Shares Outstanding
206.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.87
EPS
$-1.07
Book Value
$-2.21
P/E Ratio
-5.6x
Price/Sales (TTM)
3.6
Price/Cash Flow (TTM)
---
Operating Margin
-33.43%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.